A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

Blood

Volumn 100, Issue 6, 2002, Pages 1965-1971

  Ottmann, Oliver G ^a   Druker, Brian J ^b   Sawyers, Charles L ^c   Goldman, John M ^d   Reiffers, Jose ^e   Silver, Richard T ^f   Tura, Sante ^g   Fischer, Thomas ^h   Deininger, Michael W ⁱ   Schiffer, Charles A ^j   Baccarani, Michele ^k   Gratwohl, Alois ^l   Hochhaus, Andreas ^m   Hoelzer, Dieter ^a   Fernandes Reese, Sofia ^c   Gathmann, Insa ^l   Capdeville, Renaud ^l   O'Brien, Stephen G ⁿ  

^a GOETHE UNIVERSITY   (Germany)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^e UNIVERSITÉ DE BORDEAUX   (France)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

ⁱ UNIVERSITY OF LEIPZIG   (Germany)

^j WAYNE STATE UNIVERSITY   (United States)

^k UNIVERSITY HOSPITAL OF UDINE   (Italy)

^l UNIVERSITY HOSPITAL BASEL   (Switzerland)

^m UNIVERSITY OF HEIDELBERG   (Germany)

ⁿ NEWCASTLE UNIVERSITY   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BCR ABL PROTEIN; COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; IMATINIB; MESSENGER RNA; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; VINCRISTINE;

ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME;

EID: 0037105560     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2001-12-0181     Document Type: Article

References (52)

1. GleissnerBGökbugetNBartramCRet alLeading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis.Blood.99200215361543
2. MaurerJJanssenJWThielEet alDetection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction.Lancet.337199110551058
3. RadichJGehlyGLeeAet alDetection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation.Blood.89199726022609
4. WestbrookCAHoobermanALSpinoCet alClinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762).Blood.80199229832990
5. SchrappeMAricoMHarbottJet alPhiladelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome.Blood.92199827302741
6. PaiettaERacevskisJBennettJMet alBiologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: the Eastern Cooperative Oncology Group experience.Leukemia.12199818811885
7. ChanLCKarhiKKRayterSIet alA novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia.Nature.3251987635637
8. ShtivelmanEGaleRPDreazenOet albcr-abl RNA in patients with chronic myelogenous leukemia.Blood.691987971973
9. Ben-NeriahYDaleyGQMes-MassonAMWitteONBaltimoreDThe chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene.Science.2331986212214
10. LugoTGPendergastAMMullerAJWitteONTyrosine kinase activity and transformation potency of bcr-abl oncogene products.Science.247199010791082
11. BediABarberJPBediGCet alBCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents.Blood.86199511481158
12. SirardCLaneuvillePDickJEExpression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism.Blood.83199415751585
13. SawyersCLChronic myeloid leukemia.N Engl J Med.340199913301340
14. FaderlSKantarjianHMThomasDAet alOutcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.Leuk Lymphoma.362000263273
15. HoelzerDGokbugetNRecent approaches in acute lymphoblastic leukemia in adults.Crit Rev Oncol Hematol.3620004958
16. RadichJPPhiladelphia chromosome-positive acute lymphocytic leukemia.Hematol Oncol Clin North Am.1520012136
17. PretiHAO'BrienSGiraltSBeranMPierceSKantarjianHMPhiladelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients.Am J Med.9719946065
18. Garcia-ManeroGThomasDASalvage therapy for refractory or relapsed acute lymphocytic leukemia.Hematol Oncol Clin North Am.152001163205
19. DekkerAWvan′t VeerMBSizooWet alIntensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia.J Clin Oncol.151997476482
20. KantarjianHMO′BrienSSmithTLet alResults of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.J Clin Oncol.182000547561
21. SnyderDSNademaneeAPO'DonnellMRet alLong-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission.Leukemia.13199920532058
22. DunlopLCPowlesRSinghalSet alBone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.Bone Marrow Transplant.171996365369
23. StockschladerMHegewisch-BeckerSKrugerWet alBone marrow transplantation for Philadelphia-chromosome-positive acute lymphoblastic leukemia.Bone Marrow Transplant.161995663667
24. CornelissenJJCarstonMKollmanCet alUnrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome.Blood.97200115721577
25. SierraJRadichJHansenJAet alMarrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.Blood.90199714101414
26. MartinTGLinkerCAAutologous stem cell transplantation for acute lymphoblastic leukemia in adults.Hematol Oncol Clin North Am.152001121143
27. MartinTGGajewskiJLAllogeneic stem cell transplantation for acute lymphocytic leukemia in adults.Hematol Oncol Clin North Am.15200197120
28. DeiningerMWGoldmanJMLydonNMeloJVThe tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.Blood.90199736913698
29. DrukerBJTamuraSBuchdungerEet alEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.Nat Med.21996561566
30. Gambacorti-PasseriniCle CoutreCPMologniLet alInhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.Blood Cells Mol Dis.231997380394
31. DrukerBJTalpazMRestaDJet alEfficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.N Engl J Med.344200110311037
32. KantarjianHSawyersCHochhausAet alHematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.N Engl J Med.3462002645652
33. TalpazMSilverRTDrukerBJet alImatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.Blood.99200219281937
34. SawyersCLHochhausAFeldmanEet alImatinib mesylate induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.Blood.99200235303539
35. DrukerBJSawyersCLKantarjianHet alActivity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.N Engl J Med.344200110381042
36. ChesonBDCassilethPAHeadDRet alReport of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.J Clin Oncol.81990813819
37. BassanRLeredeTBarbuiTStrategies for the treatment of recurrent acute lymphoblastic leukemia in adults.Haematologica.8119962036
38. ButturiniAArlinghausRBGaleRPBCR/ABL and leukemia.Leuk Res.201996523529
39. ThomasDAKantarjianHSmithTLet alPrimary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy.Cancer.86199912161230
40. BuchdungerECioffiCLLawNet alAbl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.J Pharmacol Exp Ther.2952000139145
41. HofmannWKJonesLCLempNAet alPh(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.Blood.99200218601862
42. von BubnoffNSchnellerFPeschelCDuysterJBCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study.Lancet.3592002487491
43. Gambacorti-PasseriniCBarniRle CoutrePet alRole of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.J Natl Cancer Inst.92200016411650
44. le CoutrePTassiEVarella-GarciaMet alInduction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.Blood.95200017581766
45. MahonFXDeiningerMWSchultheisBet alSelection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.Blood.96200010701079
46. WeisbergEGriffinJDMechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines.Blood.95200034983505
47. HofmannWKde VosSElashoffDet alRelation between resistance of Philadelphia-chromosome positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study.Lancet.3592002481486
48. TopalyJZellerWJFruehaufSSynergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.Leukemia.152001342347
49. KanoYAkutsuMTsunodaSet alIn vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents.Blood.97200119992007
50. ThiesingJTOhno-JonesSKolibabaKSDrukerBJEfficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells.Blood.96200031953199
51. HooverRRMahonFXMeloJVDaleyGQOvercoming STI571 resistance with the farnesyltransferase inhibitor SCH66336 [abstract].Blood9820022585a
52. PetersDGHooverRRGerlachMJet alActivity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.Blood.97200114041412